Dolat Capital: Suven Pharma Delivers Soft Q2, Growth Outlook Remains Intact
Tablets sits before packaging at a drug manufacturing unit in Kursk, Russia. (Photographer: Andrey Rudakov/Bloomberg)

Dolat Capital: Suven Pharma Delivers Soft Q2, Growth Outlook Remains Intact

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer Bl...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.